The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
follicular lymphoma
ibrutinib
rituximab
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
13
09
2019
revised:
01
11
2019
accepted:
04
11
2019
pubmed:
18
3
2020
medline:
13
1
2021
entrez:
18
3
2020
Statut:
ppublish
Résumé
This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton's tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once-daily ibrutinib 560 mg continuously plus once-weekly rituximab 375 mg/m
Identifiants
pubmed: 32180219
doi: 10.1111/bjh.16424
pmc: PMC7317728
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Rituximab
4F4X42SYQ6
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
650-660Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Pharmacyclics, LLC, an AbbVie Company
ID : Not applicable
Pays : International
Informations de copyright
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Blood. 2005 Dec 1;106(12):3725-32
pubmed: 16123223
Cancer Manag Res. 2017 Apr 24;9:131-140
pubmed: 28479860
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
J Clin Oncol. 1986 Oct;4(10):1470-80
pubmed: 3531422
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
N Engl J Med. 2018 Sep 6;379(10):934-947
pubmed: 30184451
Blood. 2019 Jul 25;134(4):353-362
pubmed: 31101627
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Blood. 2001 Jan 1;97(1):101-6
pubmed: 11133748
Blood. 2018 Jan 11;131(2):182-190
pubmed: 29074501
Blood. 2006 Nov 1;108(9):3135-42
pubmed: 16835385
Lancet Oncol. 2014 Nov;15(12):1311-8
pubmed: 25439689
J Clin Oncol. 2009 Jun 20;27(18):3036-43
pubmed: 19414675
J Clin Oncol. 1998 Aug;16(8):2780-95
pubmed: 9704731
Ann Oncol. 2017 Nov 1;28(11):2806-2812
pubmed: 28945884
Blood. 2006 Nov 15;108(10):3295-301
pubmed: 16873669
J Clin Oncol. 2004 Dec 1;22(23):4711-6
pubmed: 15483015
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
pubmed: 20615965
J Clin Oncol. 2014 Oct 1;32(28):3096-102
pubmed: 25154829
Nat Rev Cancer. 2005 Apr;5(4):251-62
pubmed: 15803153
Blood. 2016 Nov 24;128(21):2510-2516
pubmed: 27697771
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
J Clin Oncol. 2008 Oct 1;26(28):4579-86
pubmed: 18662969
J Clin Oncol. 2010 Jun 10;28(17):2902-13
pubmed: 20385990
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Blood. 2005 Feb 15;105(4):1417-23
pubmed: 15494430
Oncologist. 2018 Apr;23(4):454-460
pubmed: 29317554
Lancet Oncol. 2014 Apr;15(4):424-35
pubmed: 24602760
J Clin Oncol. 2002 Oct 15;20(20):4261-7
pubmed: 12377971